Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence

Key Findings:  This review of human and animal research on the effects of palmitoylethanolamide (PEA) on several neurobiological processes as well as improvement in language and behavior in Autism spectrum disorders (ASD). PEA also has a role in immunity, inflammation, neuron plasticity, regeneration, and apoptosis possibly through activation of PPAR-α receptors. Its overall safety profile makes PEA a possible therapeutic option for the treatment of ASD.

Type of Study:  Meta-analysis

Study Result:  Positive

Study Location(s):  Italy, United Kingdom

Year of Pub:  2021

Cannabinoids Studied:  Endocannabinoid (unspecified), Palmitoylethanolamide (PEA)

Phytocannabinoid Source:  Not Applicable

Receptors Studied:  GPCR 55, PPAR - Alpha

Ligands Studied:  Glutamate, Pro-inflammatory cytokines